These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 64295)

  • 1. Comparison of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine and cytosine arabinoside in the treatment of murine brain tumor.
    Basler GA; Shapiro WR
    Cancer Treat Rep; 1976 Jul; 60(7):875-9. PubMed ID: 64295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.
    Kreis W; Gordon CS; DeJager R; Krakoff IH
    Cancer Res; 1975 Sep; 35(9):2453-60. PubMed ID: 1149046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tissue distribution and fate of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine and 1-beta-D-arabinofuranosyl-5-fluorocytosine in rats.
    Chou TC; Vidal P; Phillips FS
    Cancer Treat Rep; 1977 Jul; 61(4):617-24. PubMed ID: 69496
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative ultrastructure of submaxillary salivary glands from mice treated with cytosine arabinoside, cyclocytidine, and anhydro-ara-5-fluorocytidine.
    Liss RH; Charest MC; Mead JA
    Cancer Treat Rep; 1976 Jul; 60(7):881-8. PubMed ID: 64296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologic disposition of cytosine arabinoside and its derivatives in man.
    Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
    Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of the combination of cis-platinum diamminodichloride and 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in transplanted mouse leukemias.
    Burchenal JH; O'Toole T; Kalaher K; Chisholm J
    Cancer Res; 1977 Nov; 37(11):4098-100. PubMed ID: 71204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
    Chou TC; Hutchinson DJ; Schmid FA; Philips FS
    Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
    Tanaka M; Kimura K; Yoshida S
    Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
    Hong F; Mayhew E
    Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM; Rustum YM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites.
    Rustum YM; Danhauser L; Luccioni C; Au JL
    Cancer Treat Rep; 1981; 65 Suppl 3():73-82. PubMed ID: 7049369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.
    Ross DD; Chen SR; Cuddy DP
    Cancer Res; 1990 May; 50(9):2658-66. PubMed ID: 2328491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
    Ho DH; Neil GL
    Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.